Escrow Technology Sample Clauses

Escrow Technology. RIBOZYME shall from time to time place into escrow ----------------- written descriptions of its manufacturing and quality control procedures as may be necessary for ATUGEN to fully manufacture the Nucleic Acid Molecules ("Escrow Technology"). To facilitate the provisions of this Section 8.7, RIBOZYME shall promptly establish such escrow account and provide ATUGEN periodic reports of its transfer of information to such account. In the event that RIBOZYME cannot adequately supply ATUGEN with its requirements of the Nucleic Acid Molecules within 45 days of written request therefore, as to amounts or in accordance with ATUGEN's specifications, ATUGEN shall have the right to access the Escrow technology to manufacture or have manufactured the Nucleic Acid Molecules. RIBOZYME's intellectual property trade secrets related to such technology transfer shall be treated as Confidential Information of RIBOZYME under Article 4. Specifically, manufacture by third parties will require the same degree of protection that ATUGEN uses for its most important confidential information. In the event of a Change in Control of RIBOZYME, ATUGEN shall be entitled to continued access to the Escrow [*] Confidential treatment requested Technology necessary for ATUGEN to manufacture the Nucleic Acid Molecules for use in the Field.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Escrow Technology. RPI shall from time to time place into escrow written ----------------- descriptions of its manufacturing and quality control procedures as may be necessary for ATUGEN to fully manufacture Ribozymes. ("Escrow Technology") To facilitate the provisions of this section 2.5, RPI shall promptly establish such escrow account and provide ATUGEN periodic reports of its transfer of information to such account. In the event that RPI cannot adequately supply ATUGEN with its requirements of the Ribozymes within 45 days of written request therefore, as to amounts or in accordance with ATUGEN's specifications, ATUGEN shall have the right to access the Escrow technology to manufacture or have manufactured the Ribozymes. RPI's intellectual property trade secrets related to such technology transfer shall be treated as Confidential Information of RPI under Section 4. Specifically, manufacture by third parties will require the same degree of protection that ATUGEN uses for its most important confidential information. In the event of a Change in Control of RPI, ATUGEN shall be entitled to continued access to the Escrow Technology necessary for ATUGEN to manufacture the Ribozymes for use in the Field.
Sample 1Sample 2

Related to Escrow Technology

  • New Technology If New Technology becomes available from any source, including Supplier, then KP may evaluate and contract with any supplier so that KP will have access to New Technology at all times. If Supplier cannot offer New Technology at comparable or lower prices, KP may either (a) amend contract pricelist to add Supplier's New Technology at a mutually agreed-upon price; or (b) contract with other suppliers for New Technology. Regardless of whether New Technology is added to this Agreement, Supplier and KP will negotiate in good faith to equitably adjust the pricing for any current Product under this Agreement affected by the New Technology.

  • Joint Technology The Parties agree that, in order to effectuate the provisions of Section 4.4.2, subject to any exclusive licenses granted hereunder, (a) the non-use provisions of this Article 9 shall not apply to each Party’s use of Joint Technology, and (b) each Party may disclose the Joint Technology to Third Parties who are under terms of confidentiality no less strict than those contained in this Agreement.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Technology For purposes of this Agreement, “Technology” means all Software, information, designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs, subroutines, tools, materials, specifications, processes, inventions (whether or not patentable and whether or not reduced to practice), apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other embodiments of any of the foregoing, in any form or media whether or not specifically listed herein. Further, for purposes of this Agreement, “Software” means any and all computer programs, whether in source code or object code; databases and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing; and all documentation, including user manuals and other training documentation, related to any of the foregoing.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Patent Rights The term “

  • Intellectual Property, Inventions and Patents Executive acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports, patent applications, copyrightable work and mask work (whether or not including any confidential information) and all registrations or applications related thereto, all other proprietary information and all similar or related information (whether or not patentable) which relate to Parent’s or any of its Subsidiaries’ actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by Executive (whether alone or jointly with others) while employed by the Company and its Subsidiaries, whether before or after the date of this Agreement (“Work Product”), belong to Parent, the Company or such Subsidiary. Executive shall promptly disclose such Work Product to the Board and, at the Company’s expense, perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm such ownership (including, without limitation, assignments, consents, powers of attorney and other instruments).

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

Time is Money Join Law Insider Premium to draft better contracts faster.